Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

On the heels of two FDA approvals in lung cancer treatments, what innovations are next? As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung ...

Circulating tumor DNA (ctDNA) may help personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer (LS-SCLC), according to a study from China. Researchers ...

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer Patients were randomly assigned to ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.